Search Result

Results for "

Fibrinogen Receptor Antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (17) P-glycoprotein (1) Reference Standards (2) Thrombin (1)
By Research Areas:	Cardiovascular Disease (19)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17369B

Tirofiban Maximum Cited Publications 6 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369

Tirofiban hydrochloride monohydrate Maximum Cited Publications 6 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-120694

ML165 RUC-2	Integrin	Cardiovascular Disease
ML165 (RUC-2) is an aIIbb3 receptor antagonist. ML165 has orthosteric inhibition effect at the RGD binding domain. ML165 inhibits platelet adhesion to fibrinogen, and inhibits platelet aggregation (IC₅₀: 96 nM) .

HY-117824

L-703014	Integrin	Others
L-703014 is a fibrinogen receptor antagonist, with the IC₅₀ of 94 nM, that acts as a novel parenteral and potential oral antithrombotic agent .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369BR

Tirofiban (Standard) L700462 (Standard); MK383 (Standard)	Reference Standards Integrin	Cardiovascular Disease
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-10315

Elarofiban RWJ-53308	Integrin	Cardiovascular Disease
Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor α_IIbβ₃ (GPIIb/IIIa), with an IC₅₀ of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research .

HY-10315A

Elarofiban diTFA	Integrin	Cardiovascular Disease
Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor α_IIbβ₃ (GPIIb/IIIa), with an IC₅₀ of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research .

HY-19163

SC-52012	Integrin	Cardiovascular Disease
HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.

HY-118410

L-738167	Integrin	Cardiovascular Disease
L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research .

HY-169836

Des-ethyl-carafiban	Integrin	Cardiovascular Disease
Des-ethyl-carafiban (Compound 44) is a fibrinogen receptor antagonist that can effectively inhibit platelet aggregation induced by multiple agonists. Des-ethyl-carafiban can be used in the research of thrombotic diseases .

HY-106932

L-734217	Integrin	Cardiovascular Disease
L-734217 is an orally active and potent **fibrinogen receptor** antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders .

HY-10313

ZD 2486	Integrin	Cardiovascular Disease
ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. ZD 2486 inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor on platelets. ZD 2486 can be used for the study of conditions related to unwanted platelet aggregation, such as acute coronary syndrome, unstable angina pectoris, acute myocardial infarction, and complications from cardiovascular interventional procedures ^[1]

HY-17369R

Tirofiban hydrochloride monohydrate (Standard) L700462 hydrochloride monohydrate (Standard); MK383 hydrochloride monohydrate (Standard)	Reference Standards Integrin	Cardiovascular Disease
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits *fibrinogen* binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-106394

TP-9201	P-glycoprotein	Cardiovascular Disease
TP-9201 is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. TP-9201 inhibits the interaction between GPIIb/IIIa and fibrinogen, thereby suppressing platelet aggregation. TP-9201 exhibits similar inhibitory activity on adenosine diphosphate (ADP) (HY-W010918)-induced platelet aggregation in humans, baboons, and dogs (IC₅₀ = 1-3 μM), while showing lower activity in rabbits (IC₅₀ = 45 μM) and rats (IC₅₀ = 20 μM). TP-9201can be used in studies related to the prevention of rethrombosis after arterial thrombolysis .

HY-P11416

Ac-RGDS-NH2	Integrin	Cardiovascular Disease
Ac-RGDS-NH2, a tetrapeptide, is an integrin antagonist. Ac-RGDS-NH2 competitively binds to the GPIIb/IIIa receptor (K_i = 4.2 μM), inhibiting the binding of fibrinogen to platelets and thereby effectively suppressing platelet aggregation. Ac-RGDS-NH2 can be used for research on thrombosis .

HY-P0038

MK-852 L-367073	Integrin	Cardiovascular Disease
MK-852 (L-367073) is an effective GPIIb/IIIa receptor antagonist. MK-852 can significantly inhibit the binding of fibrinogen to platelets in vitro. MK-852can be used for the study of thrombosis .

HY-19175

FK 633 FR-144633	Thrombin Integrin	Cardiovascular Disease
FK 633 (FR-144633) is a *fibrinogen* inhibitor and peptide mimetic GPⅡbⅡa receptor antagonist. FK 633 has anti-platelet and anti-thrombotic effects. FK 633 inhibits ADP-, collagen-, thrombin-, and PAF-induced platelet aggregation with IC₅₀ values of 103, 87, 98, and 239 nM, respectively .

HY-167848

DMP-728 free base XL-118	Others	Cardiovascular Disease
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC₅₀ of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .

Cat. No.	Product Name	Target	Research Area

HY-P11416

Ac-RGDS-NH2	Integrin	Cardiovascular Disease
Ac-RGDS-NH2, a tetrapeptide, is an integrin antagonist. Ac-RGDS-NH2 competitively binds to the GPIIb/IIIa receptor (K_i = 4.2 μM), inhibiting the binding of fibrinogen to platelets and thereby effectively suppressing platelet aggregation. Ac-RGDS-NH2 can be used for research on thrombosis .

HY-P0038

MK-852 L-367073	Integrin	Cardiovascular Disease
MK-852 (L-367073) is an effective GPIIb/IIIa receptor antagonist. MK-852 can significantly inhibit the binding of fibrinogen to platelets in vitro. MK-852can be used for the study of thrombosis .

HY-P1711

L 366763	Peptides	Cardiovascular Disease
L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.